PDF Cover

Percutaneous Transhepatic Cholangiography Market

The market for Percutaneous Transhepatic Cholangiography was estimated at $754 million in 2024; it is anticipated to increase to $1.22 billion by 2030, with projections indicating growth to around $1.81 billion by 2035.

Report ID:DS1801089
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Percutaneous Transhepatic Cholangiography
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Percutaneous Transhepatic Cholangiography Market Outlook

Revenue, 2024

$754M

Forecast, 2034

$1.67B

CAGR, 2025 - 2034

8.3%

The Percutaneous Transhepatic Cholangiography (PTC) industry revenue is expected to be around $816.9 million in 2025 and expected to showcase growth with 8.3% CAGR between 2025 and 2034. Building on this projected expansion, the percutaneous transhepatic cholangiography market continues to gain clinical importance due to the rising prevalence of hepatobiliary disorders, including bile duct obstructions and malignancies. Increasing incidence of gallstones, pancreatic cancer, and postoperative biliary complications is strengthening procedural demand across tertiary care centers. Advancements in interventional radiology, improved imaging precision, and minimally invasive treatment preferences are further accelerating adoption. Healthcare systems are prioritizing early diagnostic accuracy and image-guided drainage procedures to reduce surgical risks and hospital stays. Growing geriatric populations, higher awareness of liver health, and expanding access to specialized care in emerging economies are reinforcing market relevance. Additionally, the integration of fluoroscopic and ultrasound guidance technologies continues to enhance safety outcomes, positioning PTC as a critical component of modern hepatobiliary management strategies.

Percutaneous transhepatic cholangiography is a minimally invasive imaging and interventional procedure used to visualize the biliary tree by inserting a contrast needle through the liver into the bile ducts under imaging guidance. It plays a vital role in diagnosing strictures, tumors, bile leaks, and obstructive jaundice, while also enabling therapeutic interventions such as biliary drainage and stent placement. In many cases, it serves as an alternative when endoscopic retrograde cholangiopancreatography (ERCP) is unsuccessful or contraindicated. The procedure often supports catheter-based drainage systems, and in certain complex infections, adjunctive measures such as a cholecystostomy tube may be considered for temporary decompression. Recent trends include increased adoption of image-guided precision techniques, disposable interventional kits, and hybrid operating suites, all of which are contributing to higher procedural efficiency and improved patient recovery outcomes.

Percutaneous Transhepatic Cholangiography market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Percutaneous Transhepatic Cholangiography Market Outlook

Market Key Insights

  • The Percutaneous Transhepatic Cholangiography market is projected to grow from $754.3 million in 2024 to $1.67 billion in 2034. This represents a CAGR of 8.3%, reflecting rising demand across Diagnostic Imaging, Therapeutic Intervention, and Guide for Surgical Procedures.

  • Boston Scientific, Cook Medical, Advin Health Care are among the leading players in this market, shaping its competitive landscape.

  • U.S. and China are the top markets within the Percutaneous Transhepatic Cholangiography market and are expected to observe the growth CAGR of 6.1% to 8.7% between 2024 and 2030.

  • Emerging markets including India, Brazil and South Korea are expected to observe highest growth with CAGR ranging between 8.0% to 10.4%.

  • Transition like Transition from Diagnostic-Centric Use to Integrated Diagnostic and Therapeutic Platforms is expected to add $107 million to the Percutaneous Transhepatic Cholangiography market growth by 2030.

  • The Percutaneous Transhepatic Cholangiography market is set to add $920 million between 2024 and 2034, with manufacturer targeting Jaundice & Gallstones Application projected to gain a larger market share.

  • With Rising prevalence of gallbladder diseases, and progressive Technological Innovations, Percutaneous Transhepatic Cholangiography market to expand 122% between 2024 and 2034.

percutaneous transhepatic cholangiography market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Percutaneous Transhepatic Cholangiography - Country Share Analysis

Opportunities in the Percutaneous Transhepatic Cholangiography

The integration of artificial intelligence and machine learning into imaging platforms presents significant opportunities for percutaneous transhepatic cholangiography. AI-assisted ultrasound and fluoroscopic guidance can enhance needle placement accuracy, optimize contrast utilization, and reduce procedure times, making PTC safer and more efficient. Enhanced imaging analytics may also support predictive risk stratification, driving clinician confidence and broader use. This technological innovation is expected to boost PTC demand in advanced healthcare centers where precision and workflow optimization are prioritized, thus increasing overall procedural volume.

Growth Opportunities in North America and Asia-Pacific

North America continues to dominate the percutaneous transhepatic cholangiography market with the largest share of global revenue, driven by advanced healthcare infrastructure, high procedural adoption, and strong reimbursement frameworks that favor minimally invasive diagnostics and interventions. The United States and Canada lead due to high incidence rates of hepatobiliary diseases and well-established interventional radiology capabilities that prioritize real-time imaging and patient outcomes. Favorable regulatory support accelerates new device introductions and adoption, while robust clinical research fosters continuous innovation in imaging systems and catheter solutions. Competition is intense among major medical device players supplying cholangiography and biliary intervention technologies, influencing pricing and supplier power. Key opportunities arise from demand for integrated diagnostic-therapeutic platforms and outpatient procedure growth. However, premium procedural costs and stringent payer requirements in some states temper expansion, making tailored market strategies crucial for providers and manufacturers.
The Asia Pacific region is one of the fastest-growing markets for percutaneous transhepatic cholangiography due to rapidly improving healthcare infrastructure, rising prevalence of liver and biliary disorders, and expanding medical expenditure in countries such as China, India, Japan, and South Korea. Healthcare modernization efforts and urban hospital expansion are accelerating the adoption of minimally invasive procedures, including PTC, supported by government health initiatives and growing awareness of early diagnostics. Competition is evolving as global and regional device manufacturers expand distribution and tailor solutions to cost-sensitive markets. Opportunities are especially strong in metropolitan centers where investment in advanced imaging technologies is increasing and where outpatient procedural models are emerging. Challenges include uneven healthcare access in rural areas and varying reimbursement policies, but ongoing investments and rising patient volumes are expected to sustain strong momentum.

Market Dynamics and Supply Chain

01

Driver: Increasing Prevalence of Biliary Disorders and Rising Adoption of Minimally Invasive Imaging Technologies

One of the primary market drivers for percutaneous transhepatic cholangiograph is also the growing incidence of hepatobiliary and pancreatic disorders, including bile duct obstructions, gallstones, cholangitis and related malignancies, which significantly elevates clinician demand for accurate diagnostic and interventional procedures. Aging populations with lifestyle changes are also contributing to a larger patient pool requiring advanced imaging and drainage solutions to manage these complex conditions effectively. This trend increases procedural volumes in both hospital and specialty radiology settings. In parallel, technological advancements in medical imaging systems, such as the integration of enhanced real-time fluoroscopy with ultrasound guidance and improved catheter designs, are also improving procedural precision and safety, making PTC a preferred choice over more invasive open surgeries. These innovations shorten procedure time, reduce patient risk, and broaden clinical acceptance, especially in tertiary care centers where minimizing recovery times and maximizing diagnostic clarity are also crucial. Adoption of such imaging technologies continues to expand the scope of applications and reinforces market growth.
A key driver accelerating the PTC market is also the global shift toward minimally invasive diagnostic and therapeutic procedures. Patients and healthcare providers increasingly favor percutaneous approaches that reduce hospital stays, lower complication rates and support faster recovery compared with traditional open surgeries. PTC fits this trend as it delivers access to the biliary system with precision and less trauma, particularly when combined with advanced guidance systems and stent placement techniques. Additionally, expanding healthcare infrastructure in emerging markets and increased investment in interventional radiology capabilities in developed regions are also enhancing access to PTC procedures. Hospitals and specialty centers now integrate PTC into routine care pathways for hepatobiliary diseases, supported by reimbursement frameworks in countries like the United States and parts of Europe that favor cost-effective and outcome-oriented interventions. This broader availability and healthcare modernization is also a strong enabler for sustained market uptake globally.
02

Restraint: Limited Skilled Interventional Radiologists and High Procedural Complexity

A major restraint for PTC is the limited availability of skilled interventional radiologists combined with the procedure’s technical complexity. PTC demands high precision, thorough training, and experience to avoid complications such as bleeding, bile leaks, or infection. In regions with constrained specialist resources especially in rural or emerging markets providers may defer or avoid PTC, lowering procedure volumes and market revenue. For example, under-resourced hospitals may rely on ERCP or referral to tertiary centers, reducing overall demand. This skills gap also increases training costs and slows adoption of advanced PTC techniques, hindering broader market expansion and procedural standardization.
03

Opportunity: Expanding Use of PTC in Emerging Asian and Latin American Healthcare Markets with Growing Hospital Infrastructure and Growth in Therapeutic PTC Use for Geriatric Patients with Complex Biliary Conditions

Emerging healthcare systems in Asia Pacific and Latin America are investing heavily in hospital infrastructure, including interventional radiology suites capable of performing percutaneous transhepatic cholangiography. These regions have growing incidences of hepatobiliary diseases but historically limited access to advanced imaging procedures. As hospitals expand and upgrade diagnostic and minimally invasive therapy capabilities, PTC adoption is expected to rise rapidly. Growth will be strongest in tertiary care centers integrating PTC into diagnostic imaging and therapeutic intervention pathways, especially where endoscopic options like ERCP are less accessible, creating substantial untapped demand.
The global increase in geriatric populations is driving demand for minimally invasive procedures, particularly among older patients with complex biliary obstructions, cholangitis, or post-surgical complications. PTC offers effective diagnostic and therapeutic solutions with lower risk compared to open surgery, making it highly suitable for frail patients. As clinicians focus on age-friendly care pathways that reduce recovery times and hospital stays, PTC utilization in therapeutic interventions such as biliary drainage and stenting is expected to grow substantially in regions with ageing demographics.
04

Challenge: High Cost of Advanced Imaging Systems and Reimbursement Variability Limits Adoption

Another key restraint is the high acquisition and maintenance cost of advanced imaging equipment and inconsistent reimbursement frameworks across regions. Fluoroscopy suites integrated with ultrasound guidance, digital contrast systems, and catheter technologies require significant capital investment. Hospitals operating on tight budgets may delay upgrades or limit PTC availability, suppressing demand growth. In addition, reimbursement variability such as lower or uncertain coverage for PTC in certain public or private health plans discourages investment in equipment and training. As a result, some providers prioritize more routinely reimbursed procedures, affecting overall market dynamics and reducing projected revenue streams in price-sensitive healthcare systems.

Supply Chain Landscape

1

Raw Material Suppliers

DuPontBASF
2

Medical Equipment Manufacturers

Johnson & JohnsonMedtronic
3

Device Module Producers

Philips HealthcareGE Healthcare
4

Healthcare Providers

Mayo ClinicCleveland Clinic
Percutaneous Transhepatic Cholangiography - Supply Chain

Use Cases of Percutaneous Transhepatic Cholangiography in Diagnostic Imaging & Guide for Surgical Procedures

Diagnostic Imaging : Percutaneous transhepatic cholangiography is widely used for high precision diagnostic imaging of the biliary tree, particularly in patients with suspected obstructive jaundice, bile duct strictures, or hepatobiliary malignancies. Conventional fluoroscopy guided PTC is most commonly utilized in this application, often supported by ultrasound guidance to ensure accurate needle placement into dilated bile ducts. This technique provides detailed visualization of biliary anatomy when endoscopic retrograde cholangiopancreatography is unsuccessful or contraindicated. Its key advantage lies in delivering clear delineation of obstruction levels and bile leaks, enabling clinicians to determine disease severity and plan further management with greater diagnostic confidence.
Therapeutic Intervention : In therapeutic settings, interventional PTC is primarily employed for biliary drainage, stent placement, and stone extraction. Image guided PTC with catheter based drainage is most frequently used in hospitals and specialized interventional radiology centers. It allows direct decompression of obstructed bile ducts, reducing infection risk and relieving symptoms such as cholangitis and severe jaundice. The procedure also facilitates internal or external biliary drainage and supports targeted drug delivery in selected cases. Its minimally invasive nature lowers surgical risk, shortens hospital stays, and provides an effective alternative for high risk surgical patients.
Guide for Surgical Procedures : PTC also serves as an essential guide during complex hepatobiliary surgeries. Preoperative PTC with contrast mapping is commonly used to outline biliary anatomy before tumor resection, liver transplantation, or reconstructive surgery. Surgeons rely on detailed ductal visualization to avoid intraoperative injury and ensure precise anastomosis. In some cases, temporary biliary catheters placed during PTC remain in situ to assist intraoperative navigation. This application improves surgical planning, enhances safety margins, and reduces postoperative complications, making it particularly valuable in tertiary care centers managing advanced biliary disorders.

Impact of Industry Transitions on the Percutaneous Transhepatic Cholangiography Market

As a core segment of the Medical Device industry, the Percutaneous Transhepatic Cholangiography market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Diagnostic-Centric Use to Integrated Diagnostic and Therapeutic Platforms and Shift Toward Outpatient and Value-Based Care Delivery Models have redefined priorities across the Medical Device sector, influencing how the Percutaneous Transhepatic Cholangiography market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Diagnostic-Centric Use to Integrated Diagnostic and Therapeutic Platforms

PTC is transitioning from a primarily diagnostic imaging procedure to a dual diagnostic and therapeutic platform integrated within interventional radiology suites. Hospitals increasingly adopt bundled biliary intervention solutions that combine imaging, drainage catheters, and stent placement capabilities in a single care pathway. This shift is impacting adjacent industries such as medical device manufacturing and hospital procurement, where demand is moving toward comprehensive solution providers rather than standalone imaging suppliers. For example, vendors offering combined imaging systems and disposable interventional kits are capturing higher contract values, reshaping revenue models and strengthening long-term service agreements across tertiary healthcare networks.
02

Shift Toward Outpatient and Value-Based Care Delivery Models

Another major industry transition is the movement of PTC into outpatient and value-based care frameworks. As healthcare systems prioritize cost efficiency and shorter hospital stays, suitable biliary drainage and guided intervention cases are increasingly performed in advanced ambulatory centers. This transition influences healthcare infrastructure planning, reimbursement strategies, and medical equipment leasing markets. Imaging technology providers are responding with compact, cost-efficient fluoroscopy platforms tailored for smaller facilities. The change enhances competitive intensity while encouraging partnerships between device manufacturers and outpatient providers, ultimately expanding procedural access while optimizing operating margins across the broader hepatobiliary care ecosystem.